{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-24-000074","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.269702+00:00","generated_at":"2026-05-30T04:10:45.241855+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ligand Q3 revenue $51.8M (+58% YoY); raises 2024 guidance to $160-165M revenue, $5.50-5.70 adj EPS","bullets":["Q3 total revenues & other income $51.8M (vs $32.9M); royalties $31.7M (+33% YoY) on QARZIBA and FILSPARI growth.","GAAP net loss from continuing ops $7.2M ($0.39 loss/sh); core adj net income $35.3M ($1.84/sh) vs $18.0M ($1.02).","Raised 2024 guidance: revenue now $160-165M (prev $140-157M); adj EPS $5.50-5.70 (prev $5.00-5.50).","Received $13.5M milestone upon Ohtuvayre commercial launch; cash & investments $219.6M including $63.3M in VKTX stock.","Issued 334,325 shares under ATM at avg $104.70 for gross $35M; up to $65M remains available."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-24-000074","json":"https://secwatch.observer/filing/0000886163-24-000074.json","markdown":"https://secwatch.observer/filing/0000886163-24-000074.md","text":"https://secwatch.observer/filing/0000886163-24-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000074/0000886163-24-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000074/lgnd-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:10:45.241855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}